You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
Mendeley readers
Attention Score in Context
| Title |
Use and effectiveness of tocilizumab among patients with rheumatoid arthritis: an observational study from the British Society for Rheumatology Biologics Register for rheumatoid arthritis
|
|---|---|
| Published in |
Clinical Rheumatology, December 2016
|
| DOI | 10.1007/s10067-016-3485-5 |
| Pubmed ID | |
| Authors |
Mari Kihara, Rebecca Davies, Lianne Kearsley-Fleet, Kath D. Watson, Mark Lunt, Deborah P.M. Symmons, Kimme L. Hyrich |
| Abstract |
The aims of the present study are to describe the characteristics of rheumatoid arthritis (RA) patients selected for tocilizumab (TCZ), compare the "real-world" effectiveness of TCZ and tumour necrosis factor inhibitors (TNFi) when used as a first biologic and assess the influence of past biologic exposure/concurrent methotrexate (MTX) therapy on post-TCZ treatment outcomes. The British Society for Rheumatology Biologics Register (BSRBR-RA) is a prospective cohort study following RA patients starting biologics in the UK. This includes patients starting TCZ as first or subsequent biologic, alongside biologic-naïve patients starting TNFi. Six-month disease activity and 1-year drug survival were compared between biologic-naïve patients starting TCZ versus TNFi and first-line versus subsequent TCZ users and TCZ users with MTX versus without using regression models adjusted by propensity score. Two hundred seventeen patients started TCZ, and 2419 started TNFi as first biologic. Seven hundred seventy-seven started TCZ after other biologics. First-line TCZ users had a higher prevalence of pulmonary fibrosis and cancer history than TNFi users. The first-line TCZ users were more likely to achieve DAS28 remission at 6 months than first-line TNFi, but other improvement markers were similar. The treatment response at 6 months was similar between subsequent-line TCZ users and first-line users after adjusting for baseline patient differences. Concurrent MTX use was not associated with treatment response in either first- or subsequent-line TCZ users. TCZ has been primarily used as subsequent-line biologic in the UK. When used as first line, the response appears similar to that observed in patients starting TNFi, suggesting that clinical response alone should not decide between initial biologic therapies. |
Mendeley readers
The data shown below were compiled from readership statistics for 90 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 90 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 14 | 16% |
| Student > Ph. D. Student | 10 | 11% |
| Student > Postgraduate | 7 | 8% |
| Student > Master | 7 | 8% |
| Student > Bachelor | 7 | 8% |
| Other | 24 | 27% |
| Unknown | 21 | 23% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 37 | 41% |
| Pharmacology, Toxicology and Pharmaceutical Science | 10 | 11% |
| Biochemistry, Genetics and Molecular Biology | 5 | 6% |
| Nursing and Health Professions | 3 | 3% |
| Social Sciences | 3 | 3% |
| Other | 8 | 9% |
| Unknown | 24 | 27% |
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 14 September 2017.
All research outputs
#7,523,962
of 22,961,203 outputs
Outputs from Clinical Rheumatology
#1,162
of 3,038 outputs
Outputs of similar age
#138,197
of 416,284 outputs
Outputs of similar age from Clinical Rheumatology
#11
of 40 outputs
Altmetric has tracked 22,961,203 research outputs across all sources so far. This one is in the 44th percentile – i.e., 44% of other outputs scored the same or lower than it.
So far Altmetric has tracked 3,038 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.9. This one is in the 49th percentile – i.e., 49% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 416,284 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 54% of its contemporaries.
We're also able to compare this research output to 40 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 62% of its contemporaries.